Literature DB >> 19192668

Osteopontin expression profiles predict pathological and clinical outcome in breast cancer.

Neill Patani1, Fadi Jouhra, Wen Jiang, Kefah Mokbel.   

Abstract

BACKGROUND: Osteopontin (OPN) overexpression in breast cancer has been associated with adverse pathological and clinical outcomes. In this study, the OPN expression profiles were examined in a cohort of breast cancer patients. PATIENTS AND METHODS: RNA extraction and reverse transcription were performed on breast carcinomas (n = 127) and normal tissues (n = 33). Transcript levels were determined using real-time PCR.
RESULTS: The OPN-a levels decreased with increasing TNM stage and worse clinical outcome. The OPN-b levels increased with tumour grade and Nottingham Prognostic Index (NPI) stage, were higher in patients who died of breast cancer than in those who were disease-free after 10 years and predicted disease-free survival. The OPN-c expression was associated with tumour grade and poor prognosis. Furthermore, the expression levels predicted local recurrence, disease-free survival and bone metastases.
CONCLUSION: OPN expression profiles are significantly associated with tumour grade, stage and patient prognosis in breast cancer. OPN-c is likely to be of particular utility as a prognostic marker and should be included in future validation studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19192668

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  25 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

2.  Significance of plasma osteopontin levels in patients with bladder urothelial carcinomas.

Authors:  Li Zhao; Yalin Wang; Nan Qu; Chen Huang; Lijun Chen
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

3.  Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation.

Authors:  Devanshi Seth; Alastair Duly; Paul C Kuo; Geoffrey W McCaughan; Paul S Haber
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

4.  The potential of osteopontin as a therapeutic target for human colorectal cancer.

Authors:  Wang Likui; Wang Hong; Zhang Shuwen; You Yuangang; Wen Yan
Journal:  J Gastrointest Surg       Date:  2011-02-12       Impact factor: 3.452

Review 5.  Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers.

Authors:  Thomas E Kruger; Andrew H Miller; Andrew K Godwin; Jinxi Wang
Journal:  Crit Rev Oncol Hematol       Date:  2013-09-07       Impact factor: 6.312

6.  Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients.

Authors:  Matthias Bache; Matthias Kappler; Henri Wichmann; Swetlana Rot; Antje Hahnel; Thomas Greither; Harun M Said; Matthias Kotzsch; Peter Würl; Helge Taubert; Dirk Vordermark
Journal:  BMC Cancer       Date:  2010-04-08       Impact factor: 4.430

7.  Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry.

Authors:  Jing Li; Guang-Zhi Yang; Zi-Man Zhu; Zhi-Yong Zhou; Lin Li
Journal:  Exp Ther Med       Date:  2012-01-30       Impact factor: 2.447

Review 8.  The RUNX family in breast cancer: relationships with estrogen signaling.

Authors:  N-O Chimge; B Frenkel
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

9.  Down-regulation of osteopontin mediates a novel mechanism underlying the cytostatic activity of TGF-β.

Authors:  Jing Zhang; Osamu Yamada; Shinya Kida; Yoshihisa Matsushita; Toshio Hattori
Journal:  Cell Oncol (Dordr)       Date:  2015-11-19       Impact factor: 6.730

10.  Investigation of the Osteopontin isoforms expression in patients with acute myeloid leukemia.

Authors:  Shirin Ferdowsi; Seyed H Ghaffari; Sahar Tavakkoli Shiraji; Seyed Asadollah Mousavi; Saeed Mohammadi
Journal:  Med Oncol       Date:  2021-07-27       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.